<DOC>
	<DOC>NCT01911455</DOC>
	<brief_summary>In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).</brief_summary>
	<brief_title>Study of Acamprosate in Fragile x Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Diagnostic confirmation of full mutation FXS Age â‰¥5 years and &lt;23 years General good health as determined by physical exam, medical history and laboratory work up. Use of more than two psychotropic medications (medications affecting behavior). Unstable dosing of any psychotropic medication (medication affecting behavior) Problems with kidney functioning Unstable seizure disorder Change in any anticonvulsant drug dosing in the 60 days prior to study entry Prior adequate treatment trial with acamprosate as determined by the study doctor Pregnant or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Fragile X Syndrome</keyword>
</DOC>